Skip Nav Destination
Issues
1 November 2020
-
Cover Image
Cover Image
In this issue of Molecular Cancer Therapeutics, Jin and colleagues describe the discovery and mechanism of novel anti-CD73 antibody (Hu001) and CD73-ADC (Hu001-MMAE). High CD73 staining was found in lung cancer epithelial tumor cells and stromal cells in tumor microenvironment, pictured on our cover. The anti-tumor efficacy of Hu001 required both the Fc-dependent cell-mediated cytotoxicity and a multifaceted remodeling in the tumor immune microenvironment. The novel Hu001-MMAE elicited dramatic dual benefits in killing CD73-high tumors while simultaneously promoting the effector function in T lymphocytes and dendritic cells. Read the full article on page 2340. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
MCT First Disclosures
Author Choice
Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner; Jennifer G. Brown; Thomas Son; Michael Chiechi; Pam Li; Sharad Sharma; Hua Li; Anushka De Costa; Ying Li; Yan Chen; Ann Easton; Nicholas C. Yee-Toy; Francine Z. Chen; Sergey Gorlatov; Bhaswati Barat; Ling Huang; Christina R. Wolff; Jeff Hooley; Tim E. Hotaling; Timur Gaynutdinov; Valentina Ciccarone; James Tamura; Scott Koenig; Paul A. Moore; Ezio Bonvini; Deryk Loo
Review
Small Molecule Therapeutics
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
Nicolas Floc'h; Sangbin Lim; Sue Bickerton; Afshan Ahmed; Jonathan Orme; Jelena Urosevic; Matthew J. Martin; Darren A.E. Cross; Byoung Chul Cho; Paul D. Smith
Author Choice
Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
Bih-Rong Wei; Shelley B. Hoover; Cody J. Peer; Jennifer E. Dwyer; Hibret A. Adissu; Priya Shankarappa; Howard Yang; Maxwell Lee; Tyler J. Peat; William D. Figg; R. Mark Simpson
Large Molecule Therapeutics
Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Oliver C. Rogers; Lizamma Antony; Oren Levy; Nitin Joshi; Brian W. Simons; Susan L. Dalrymple; D. Marc Rosen; Andrew Pickering; Haoyue Lan; Heidi Kuang; Sudhir H. Ranganath; Lei Zheng; Jeffrey M. Karp; S. Peter Howard; Samuel R. Denmeade; John T. Isaacs; W. Nathaniel Brennen
Cancer Biology and Translational Studies
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S. Tewari; Michael W. Sill; Bradley J. Monk; Richard T. Penson; David H. Moore; Heather A. Lankes; Lois M. Ramondetta; Lisa M. Landrum; Leslie M. Randall; Ana Oaknin; Mario M. Leitao; Eric L. Eisenhauer; Paul DiSilvestro; Linda Van Le; Michael L. Pearl; James J. Burke; Ritu Salani; Debra L. Richardson; Helen E. Michael; David W. Kindelberger; Michael J. Birrer
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.